Imperial College London
Portrait Picture

DrBrynOwen

Faculty of Medicine, Department of Metabolism, Digestion and Reproduction

Senior Lecturer
 
 
 
//

Contact

 

bryn.owen05

 
 
//

Location

 

Commonwealth BuildingHammersmith Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Talukdar:2016:10.1016/j.cmet.2016.02.001,
author = {Talukdar, S and Zhou, Y and Li, D and Rossulek, M and Dong, J and Somayaji, V and Weng, Y and Clark, R and Lanba, A and Owen, BM and Brenner, MB and Trimmer, JK and Gropp, KE and Chabot, JR and Erion, DM and Rolph, TP and Goodwin, B and Calle, RA},
doi = {10.1016/j.cmet.2016.02.001},
journal = {Cell Metabolism},
pages = {427--440},
title = {A long-acting FGF21 molecule, PF-05231023, decreases body weight and improves lipid profile in non-human primates and Type 2 diabetic subjects},
url = {http://dx.doi.org/10.1016/j.cmet.2016.02.001},
volume = {23},
year = {2016}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - FGF21 plays a central role in energy, lipid, and glucose homeostasis. To characterize the pharmacologic effects of FGF21, we administered a long-acting FGF21 analog, PF-05231023, to obese cynomolgus monkeys. PF-05231023 caused a marked decrease in food intake that led to reduced body weight. To assess the effects of PF-05231023 in humans, we conducted a placebo-controlled, multiple ascending-dose study in overweight/obese subjects with type 2 diabetes. PF-05231023 treatment resulted in a significant decrease in body weight, improved plasma lipoprotein profile, and increased adiponectin levels. Importantly, there were no significant effects of PF-05231023 on glycemic control. PF-05231023 treatment led to dose-dependent changes in multiple markers of bone formation and resorption and elevated insulin-like growth factor 1. The favorable effects of PF-05231023 on body weight support further evaluation of this molecule for the treatment of obesity. Longer studies are needed to assess potential direct effects of FGF21 on bone in humans.
AU  - Talukdar,S
AU  - Zhou,Y
AU  - Li,D
AU  - Rossulek,M
AU  - Dong,J
AU  - Somayaji,V
AU  - Weng,Y
AU  - Clark,R
AU  - Lanba,A
AU  - Owen,BM
AU  - Brenner,MB
AU  - Trimmer,JK
AU  - Gropp,KE
AU  - Chabot,JR
AU  - Erion,DM
AU  - Rolph,TP
AU  - Goodwin,B
AU  - Calle,RA
DO  - 10.1016/j.cmet.2016.02.001
EP  - 440
PY  - 2016///
SN  - 1550-4131
SP  - 427
TI  - A long-acting FGF21 molecule, PF-05231023, decreases body weight and improves lipid profile in non-human primates and Type 2 diabetic subjects
T2  - Cell Metabolism
UR  - http://dx.doi.org/10.1016/j.cmet.2016.02.001
UR  - http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000373614100011&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=1ba7043ffcc86c417c072aa74d649202
UR  - https://www.sciencedirect.com/science/article/pii/S1550413116300493?via%3Dihub
VL  - 23
ER  -
Download